<DOC>
	<DOCNO>NCT00523315</DOCNO>
	<brief_summary>To describe patient ' compliance take Aromatase Inhibitor adjuvant treatment postmenopausal , early breast cancer see current practice</brief_summary>
	<brief_title>APOLLO ( Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Provision write informed consent Patients early breast cancer schedule receive firstline adjuvant endocrine therapy aromatase inhibitor routine clinical practice Histologically cytologically proven HR+ ( ER PR + ) Postmenopausal woman , define woman fulfil follow criterion ( local guideline ) : Age &gt; = 50 year Age &lt; 50 year amenorrhoea &gt; 12 month intact uterus FSH level within postmenopausal range ( 3040 IU/ml ) , Having undergone bilateral oophorectomy . No concomitant endocrine therapy estrogen therapy selective estrogen receptor modulators Recurrence breast cancer Known hypersensitivity aromatase inhibitor excipients Any severe concomitant condition make undesirable patient participate trial would jeopardize compliance trial protocol Previous inclusion present study Participation clinical study last 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Aromatase Inhibitor</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>compliance</keyword>
	<keyword>Naturalistic</keyword>
	<keyword>Observational</keyword>
</DOC>